Alpine Fox Capital LLC Takes Position in Novo Nordisk A/S $NVO

Key Points

• Alpine Fox Capital bought 61,000 shares of Novo Nordisk in Q3 (~$3.39M), making NVO its 5th-largest position at 1.4% of the firm's holdings.
• Other institutional investors boosted exposure—Capital International Investors holds 17.7M shares and Franklin Resources about 14.0M—contributing to roughly 11.54% institutional ownership.
• Novo Nordisk beat quarterly expectations (EPS $1.01 vs. $0.90; revenue $12.43B vs. $11.97B) and declared a $1.2751 dividend (ex-dividend Mar 30, payable Apr 8), but faces near-term regulatory and legal risk after an FDA warning on unreported semaglutide adverse events and a subsequent investor investigation.

Alpine Fox Capital LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 61,000 shares of the company's stock, valued at approximately $3,385,000. Novo Nordisk A/S makes up 1.4% of Alpine Fox Capital LLC's holdings, making the stock its 5th biggest position.

Other hedge funds have also recently bought and sold shares of the company. Capital International Investors raised its position in Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company's stock worth $982,969,000 after acquiring an additional 6,092,192 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company's stock valued at $776,016,000 after purchasing an additional 13,658,867 shares in the last quarter. Loomis Sayles & Co. L P grew its stake in shares of Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company's stock worth $867,998,000 after purchasing an additional 187,789 shares during the last quarter. Folketrygdfondet raised its holdings in shares of Novo Nordisk A/S by 1.2% in the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company's stock worth $566,659,000 after purchasing an additional 117,370 shares in the last quarter. Finally, Sustainable Growth Advisers LP raised its holdings in shares of Novo Nordisk A/S by 11.7% in the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company's stock worth $427,416,000 after purchasing an additional 649,390 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $37.99 on Friday. The company has a 50 day simple moving average of $50.14 and a 200-day simple moving average of $51.77. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57. The firm has a market capitalization of $169.61 billion, a price-to-earnings ratio of 10.95 and a beta of 0.73. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $82.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is 52.74%.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Analyst Ratings Changes

A number of analysts recently weighed in on NVO shares. Jefferies Financial Group upgraded shares of Novo Nordisk A/S from an "underperform" rating to a "hold" rating in a report on Thursday, February 12th. Morgan Stanley raised Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target on the stock in a report on Tuesday, March 3rd. TD Cowen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $42.00 price objective for the company. in a research report on Tuesday, March 10th. Nordea Equity Research cut Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. Finally, Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $49.93.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.